← Evidence map

TrialRMD open2026

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Victoria Navarro-Compán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

3 trials

NCT03928704phase 3274 enrolled2019 NCT03928743phase 3332 enrolled2019 NCT04436640phase 3508 enrolled2020

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. | OpenQuestion